All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-02-17T09:55:48.000Z

FDA grants regenerative medicine advanced therapy and fast-track designation to equecabtagene autoleucel for RRMM

Feb 17, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM

Bookmark this article

On February 12, 2023, it was announced that equecabtagene autoleucel (previously known as CT103A), a BCMA-directed CAR T-cell therapy received both regenerative medicine advanced therapy and fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) multiple myeloma (MM). This follows the orphan drug designation in February 2022 and investigational new drug approval by the U.S FDA in December 2022.1

The Multiple Myeloma Hub previously reported the phase I clinical data of equecabtagene autoleucel in patients with RRMM which demonstrated increased persistency and efficacious responses, including those treated with prior murine BCMA CAR T-cell treatment. The updated phase Ib/II study results of the ongoing FUMANBA-1 trial (NCT05066646) were presented by Li2 during the European Hematology Association (EHA) 2022 Congress. Key results at the data cut off for the 79 evaluable patients with RRMM who were previously treated with at least three lines of therapy were as follows:

  • An overall response rate of 94.9%, with 68.4% achieving a complete response rate or higher.
  • A median time to response of 16 days.
  • Observed responses in patients treated with prior non-BCMA CAR T-cell therapy.
  • MRD-negativity in 92.4% overall.
  • All cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome incidences were Grade 1 and 2 and none were Grade 3 or higher.
  • Equecabtagene autoleucel demonstrated prolonged persistency and low immunogenicity.

Additional ongoing clinical trials with equecabtagene autoleucel are:

  • A phase I study combined with selinexor in patients with extramedullary RRMM and had at least three prior lines of therapy (NCT05201118).
  • A phase I study in patients with high-risk newly diagnosed MM (FUMANBA-2, NCT05181501), defined as Revised International Staging System (R-ISS) Stage 3, double-hit, or triple-hit.

  1. PR newswire. IASO Bio announces CT103A granted regenerative medicine advanced therapy (RMAT) and fast track (FT) designations by the FDA. https://www.prnewswire.com/news-releases/iaso-bio-announces-ct103a-granted-regenerative-medicine-advanced-therapy-rmat-and-fast-track-ft-designations-by-the-fda-301744775.html. Published Feb 12, 2023. Accessed Feb 15, 2023.
  2. Li C. Updated phase I/II data of safety and efficacy of CT103A, fully human BCMA-directed CAR T-cells, in relapsed/refractory multiple myeloma. Oral abstract #187. European Hematology Association 2022 Congress; Jun 12, 2022; Vienna, AT.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox